Novartis/BMS deal closes
This article was originally published in The Tan Sheet
Executive Summary
Swiss firm completes $385 mil. strategic acquisition of Mead Johnson's global adult nutritionals business from Bristol-Meyers Squibb Feb. 13. Novartis said the all-cash deal did not require any divestments for regulatory approval. The firms announced the deal in December (1"The Tan Sheet" Dec. 22, 2003, p. 12)...
You may also be interested in...
Bristol Sells Its Mead Johnson Adult Nutritionals Business To Novartis
The divestiture of Mead Johnson's adult nutritionals business to Novartis Medical Nutrition will allow the Bristol-Myers Squibb division to concentrate on its infant formula franchise
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.